Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase

European Journal of Cancer

Volumn 30, Issue 10, 1994, Pages 1408-1411

  Peters, G J ^a   van der Wilt, C L ^a   van Groeningen, C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; ENZYME INHIBITOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; RALTITREXED; THYMIDYLATE SYNTHASE;

CANCER; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

DRUG SYNERGISM; FLUOROURACIL; HUMAN; LEUCOVORIN; OXIDOREDUCTASES; PREDICTIVE VALUE OF TESTS; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0028073326     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)00218-T     Document Type: Article

References (35)

1. Clinical relevance of biochemical modulation of 5-fluorouracil
2. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid
3. Modulation of fluorouracil in patients with advanced colorectal cancer. Evidence in terms of response rate
4. Ode to methotrexate
5. Effect of folate diastereo-isomers on the binding of 5-fluoro-2′-deoxyuridine-5′-monophosphate to thymidylate synthase
6. Characteristics of thymidylate synthase purified form a human colon adenocarcinoma
7. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance
8. New targets for pyrimidine antimetabolites for the treatment of solid tumors: I thymidylate synthase
9. Quantitation of thymidylate synthase in human tumors using an ultrasensitive enzyme-linked immunoassay
10. Measurement of human thymidylate synthase (hTS) in cell lines using ELISA
11. Immunological quantification of thymidylate synthase using the monoclonal anti-body TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines
12. Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines
13. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
14. Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes
15. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and human cells
16. Basis for natural variation in sensitivity in mouse and human cells culture
17. Resistance of CCRF-CEM cloned sublines to 5-fluorodeoxyuridine associated with enhanced phosphatase activity
18. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
19. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin in combination with fluorouracil in patients with advanced colorectal carcinoma
20. Clinical pharmacokinetics of fluorouracil and folinic acid
21. Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics
22. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors
23. Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent
24. Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil
25. Thymidylate synthase (TS) gene expression predicts response of primary gastric cancer (GC) to 5-fluorouracil (5FU)-leucovorin (LV)-cisplatin (DDP)
26. Thymidylate synthase expression is an independent predictor of survival/disease free survival in patients with rectal cancer
27. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate
28. Enzymes of uracil catabolism in normal and neoplastic human tissues
29. Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flowthrough system
30. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa
31. Clinical pharmacokinetics of antimetabolites
32. Prediction of FU treatment resistance based on tumoral dihydropyrimidine dehydrogenase activity. A clinical study
33. Enhanced therapeutic efficacy of 5′ deoxy5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes
34. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
35. Good antitumour activity of the new thymidylate synthase inhibitor tomudex (ZD1694) in colorectal cancer